BeBetter Med Inc. is a biopharmaceutical firm focused on the research and development of breakthrough medications in vital therapeutic fields such as oncology, autoimmune diseases, and metabolic disorders. Established in 2012 in Guangzhou by Professor Changgeng Qian alongside a cadre of global returnees, BeBetter Med utilizes its proprietary technology platform to formulate groundbreaking pharmaceutical solutions that balance clinical effectiveness with practical utility. Guided by the ethos of "Committed to Innovation, Striving for Excellence," the company is unwavering in its commitment to independent research and to generating globally patented, safe, and effective medications.
Comprising the leadership tier of BeBetter Med Inc. is an illustrious collective of professionals, including nationally honored experts, accomplished entrepreneurs, and exceptional scientists. Together, they offer a wealth of experience in both domestic and global pharmaceutical development as well as in corporate management. Team members have been consistently honored as preeminent technological talents in the Guangzhou Development Zone and have garnered inclusion in the prestigious Guangdong "Pearl River Talent Plan" as innovative entrepreneurs.
In recognition of its contributions, BeBetter Med has been conferred the status of a Guangdong Postdoctoral Innovation Practice Base and is identified as a Guangdong Provincial New Drug Discovery and Industrialization Engineering Technology Research Center. Additionally, the company has gained acclaim as an emergent "Future Unicorn" and holds the distinction of being a "High-Tech and High-Skill" enterprise in Guangzhou.
BeBetter Med’s Pan-mutant EGFR Inhibitor BEBT-109 Phase III Clinical Trial Application is Approved by CDE
Recently, the pan-mutant EGFR inhibitor BEBT-109, developed by BeBetter Med Inc., has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration in Chinato conduct a confirmatory Phase III clinical trial fo
BeBetter Med’s First-in-Class New Drug BEBT-908 NDA Accepted
On October 8, 2023, the New Drug Application (NDA) ofBEBT-908, a class I newdrug independently developed byBeBetter Med Inc.has been officially accepted by the China National Medical Products Administration's Center for Drug Evaluation (CDE). This d
BeBetter Med Inc. successfully holds the sponsors meeting & the first general meeting of shareholders
The sponsors meeting & the first general meeting of shareholders was successfully held at the company headquarters on December 20, 2021. With the approval of all sponsors, the company was reconstructed from ‘Guangzhou BeBetter Medicine Technology Co
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号